Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies.

Morse N, Jamaspishvili T, Simon D, Patel PG, Ren KYM, Wang J, Oleschuk R, Kaufmann M, Gooding RJ, Berman DM.

Lab Invest. 2019 Jun 3. doi: 10.1038/s41374-019-0265-2. [Epub ahead of print]

PMID:
31160688
2.

MicroRNA-206 suppresses TGF-β signalling to limit tumor growth and metastasis in lung adenocarcinoma.

Watt K, Newsted D, Voorand E, Gooding RJ, Majewski A, Truesdell P, Yao B, Tuschl T, Renwick N, Craig AW.

Cell Signal. 2018 Oct;50:25-36. doi: 10.1016/j.cellsig.2018.06.008. Epub 2018 Jun 20.

PMID:
29935234
3.

Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.

Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA.

Lab Invest. 2018 Jun;98(6):839. doi: 10.1038/s41374-018-0037-4.

4.

Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.

Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA.

Lab Invest. 2018 Apr;98(4):403-413. doi: 10.1038/s41374-017-0007-2. Epub 2018 Jan 16. Review. Erratum in: Lab Invest. 2018 Mar 8;:.

5.

Critical telomerase activity for uncontrolled cell growth.

Wesch NL, Burlock LJ, Gooding RJ.

Phys Biol. 2016 Aug 8;13(4):046005. doi: 10.1088/1478-3975/13/4/046005.

PMID:
27500377
6.

Molecular characterization of Gleason patterns 3 and 4 prostate cancer using reverse Warburg effect-associated genes.

Georgescu I, Gooding RJ, Doiron RC, Day A, Selvarajah S, Davidson C, Berman DM, Park PC.

Cancer Metab. 2016 May 5;4:8. doi: 10.1186/s40170-016-0149-5. eCollection 2016.

7.

Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.

Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA.

BMC Cancer. 2013 Nov 16;13:549. doi: 10.1186/1471-2407-13-549.

8.

Enrollment of African Americans onto clinical treatment trials: study design barriers.

Adams-Campbell LL, Ahaghotu C, Gaskins M, Dawkins FW, Smoot D, Polk OD, Gooding R, DeWitty RL.

J Clin Oncol. 2004 Feb 15;22(4):730-4.

PMID:
14966098

Supplemental Content

Loading ...
Support Center